Cite
Bersanelli M, Buti S, Cortellini A, et al. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clin Med Insights Oncol. 2021;15:11795549211021667doi: 10.1177/11795549211021667.
Bersanelli, M., Buti, S., Cortellini, A., Bandini, M., Banna, G. L., Pederzoli, F., Farè, E., Raggi, D., Giannatempo, P., De Giorgi, U., Basso, U., Losanno, T., Santini, D., Mucciarini, C., Tucci, M., Tambaro, R., Farnesi, A., Caffo, O., Veccia, A., Naglieri, E., Briganti, A., Procopio, G., Pignata, S., & Necchi, A. (2021). Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clinical Medicine Insights. Oncology, 1511795549211021667. https://doi.org/10.1177/11795549211021667
Bersanelli, Melissa, et al. "Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)." Clinical Medicine Insights. Oncology vol. 15 (2021): 11795549211021667. doi: https://doi.org/10.1177/11795549211021667
Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clin Med Insights Oncol. 2021 Jul 08;15:11795549211021667. doi: 10.1177/11795549211021667. eCollection 2021. PMID: 34290538; PMCID: PMC8274126.
Copy
Download .nbib